» Authors » A Dominietto

A Dominietto

Explore the profile of A Dominietto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 545
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Furfaro E, Signori A, Di Grazia C, Dominietto A, Raiola A, Aquino S, et al.
J Antimicrob Chemother . 2019 May; 74(8):2341-2346. PMID: 31119272
Background: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. Objectives: To characterize the assessment of the blood levels...
2.
Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al.
Bone Marrow Transplant . 2015 Jun; 50 Suppl 2:S37-9. PMID: 26039205
This is a report of 148 patients with hematologic malignancies who received an unmanipulated haploidentical bone marrow transplant (BMT), followed by post-transplant high-dose cyclophosphamide (PT-CY). All patients received a myeloablative...
3.
Ghiso A, Raiola A, Gualandi F, Dominietto A, Varaldo R, Van Lint M, et al.
Bone Marrow Transplant . 2014 Oct; 50(1):56-61. PMID: 25310304
Forty-two patients relapsing after an unmanipulated haploidentical BM transplant and post-transplant CY (PT-CY), were given 108 DLI, with median interval from transplant of 266 days (range, 67-1372). DLI were given...
4.
Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola A, et al.
Clin Microbiol Infect . 2014 Mar; 20(10):O694-701. PMID: 24575948
HBsAg-negative/HBcAb-positive haematopoietic stem cell transplant (HSCT) recipients are at high risk of hepatitis B virus (HBV) reactivation. Allogeneic HSCT recipients from years 2000 to 2010 were evaluated in order to...
5.
Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al.
Bone Marrow Transplant . 2013 Nov; 49(2):190-4. PMID: 24185585
Twenty-six patients with advanced Hodgkin's disease received a related HLA haploidentical unmanipulated BMT, following a non-myeloablative conditioning with low-dose TBI, proposed by the Baltimore group; GvHD prophylaxis consisted of high-dose...
6.
Dominietto A, Tedone E, Soracco M, Bruno B, Raiola A, Van Lint M, et al.
Bone Marrow Transplant . 2011 Apr; 47(1):101-6. PMID: 21460867
We retrospectively analyzed 55 patients given a fixed dose of rituximab (200 mg) on day+5 after an alternative donor transplant, to prevent EBV DNA-emia; 68 alternative transplants who did not...
7.
Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola A, Gualandi F, et al.
Transpl Infect Dis . 2010 Jul; 12(6):505-12. PMID: 20636482
Bacteremia is a well known cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients and enterococci are among the most frequently isolated pathogens. The aim of this...
8.
Ballestrero A, Cirmena G, Dominietto A, Garuti A, Rocco I, Cea M, et al.
Int J Lab Hematol . 2009 Dec; 32(4):387-91. PMID: 19968720
Molecular monitoring of the BCR-ABL1 transcript in chronic myelogenous leukemia (CML) using quantitative real-time PCR (RQ-PCR) can be performed using either bone marrow (BM) or peripheral blood (PB). However, a...
9.
Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint M, et al.
Bone Marrow Transplant . 2009 Sep; 45(3):458-63. PMID: 19718055
A total of 46 patients with primary myelofibrosis (PMF) (median age 51 years), underwent an allogeneic hemopoietic SCT (HSCT) after a thiotepa-based reduced-intensity conditioning regimen. The median follow-up for surviving...
10.
Mikulska M, Durando P, Molinari M, Alberti M, Del Bono V, Dominietto A, et al.
J Hosp Infect . 2009 Apr; 72(2):187-8. PMID: 19376610
No abstract available.